Teva stock recovered Wednesday on surprisingly light guidance for 2026 following a decisive fourth-quarter beat.

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...